Q3 Earnings Forecast for Sanofi Issued By Leerink Partnrs

Sanofi (NASDAQ:SNY - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Sanofi in a note issued to investors on Monday, January 27th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of $1.57 for the quarter. The consensus estimate for Sanofi's current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi's Q4 2025 earnings at $0.91 EPS and FY2029 earnings at $5.88 EPS.

Separately, StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th.

Sanofi Trading Down 1.1 %

SNY traded down $0.60 during trading on Wednesday, reaching $52.37. 3,165,797 shares of the stock traded hands, compared to its average volume of 2,556,450. The stock's 50-day moving average is $48.99 and its 200 day moving average is $52.22. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $132.92 billion, a PE ratio of 26.72, a P/E/G ratio of 1.19 and a beta of 0.57.

Institutional Investors Weigh In On Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in Sanofi by 0.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company's stock valued at $15,466,000 after purchasing an additional 1,238 shares during the last quarter. AQR Capital Management LLC bought a new position in Sanofi during the 2nd quarter valued at $344,000. The Manufacturers Life Insurance Company grew its stake in shares of Sanofi by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company's stock worth $1,530,000 after acquiring an additional 6,756 shares in the last quarter. Creative Planning raised its holdings in shares of Sanofi by 9.2% in the second quarter. Creative Planning now owns 187,035 shares of the company's stock valued at $9,075,000 after purchasing an additional 15,749 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of Sanofi by 27.2% during the second quarter. NewEdge Advisors LLC now owns 29,587 shares of the company's stock valued at $1,436,000 after purchasing an additional 6,330 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.